Program: Sunday (28.10.2018)

07:30 – 09:00

Scientific Session Interactive Case Discussion

  • Mark Hertzberg
  • Andrew Lister
  • Stage IV NLPHL

    • Dennis A. Eichenauer
  • Elderly cHL

    • Joanna Romejko-Jarosinska
  • HIV-positive HL

    • Otavio Baiocchi
  • Progress on anti-PD1 moAb

    • Sven Borchmann

09:15 – 10:15

Scientific Symposium (by Chugai Pharma) Oncology meets Autoimmunity

  • Andreas Engert
  • 09:15–09:45

    Autotransplant in systemic sclerosis

    • JΓΆrg Henes
  • 09:45–10:15

    Autoimmunity in chronic GVHD

    • Daniel Wolff

10:30 – 12:00

Scientific Session Biology & Microenvironment

  • Anke van den Berg
  • Christian Steidl
  • 10:30–10:50

    Microenvironment

    • Ralf KΓΌppers
  • 10:50–11:10

    Genotyping of cHL via Liquid Biopsy

    • Davide Rossi

12:15 – 13:45

Scientific Symposium (by Takeda Oncology) Tailoring sequencing and treatment targets

  • Peter Borchmann
  • 12:15–12:20

    Welcome and introduction

    • Peter Borchmann
  • 12:20–12:35

    Considering consolidation after autologous stem cell transplantation

    • Daniel Molin
  • 12:35–12:50

    Relapse after autologous transplant: options and optimising outcomes

    • Anna Sureda
  • 12:50–13:40

    Considering patient factors: challenging cases and clinical management

    • Peter Borchmann
    • Daniel Molin
    • Anna Sureda
  • 13:40–13:45

    Summary and close

    • Peter Borchmann

14:00 – 15:30

Scientific Session Early Stages

  • Richard Hoppe
  • John Raemaekers
  • 14:00–14:20

    Early-Stage Favorable HL: HD16

    • Andreas Engert
  • 14:20–14:40

    BREACH: Randomized Phase II Trial

    • Marc AndrΓ©

15:30 – 16:00

Main Program Poster Session

16:00 – 17:30

Scientific Symposium (by Bristol-Myers Squibb) Focus on cHL: Current Insights and Future Perspectives

  • Peter Borchmann
  • 16:00–16:05

    Welcome and Introductions

    • Peter Borchmann
  • 16:05–16:25

    The Evolving cHL Treatment Landscape

    • Graham Collins
  • 16:25–16:45

    Understanding the Unmet Need in cHL

    • Peter Borchmann
  • 16:45–17:05

    Focus on Biomarkers: Biology as a Key Driver of Therapeutic Benefit

    • Margaret Shipp
  • 17:05–17:25

    Panel Discussion

    • Peter Borchmann
    • Graham Collins
    • Margaret Shipp
  • 17:25–17:30

    Concluding Remarks

    • Peter Borchmann

17:45 – 19:15

Scientific Session Survivorship & Patients’ Perspective

  • Flora van Leeuwen
  • Ananda Plate
  • 17:45–18:05

    What Patients Really Want: The Global Lymphoma Patient Survey

    • Lorna Warwick
  • 18:05–18:25

    Cognitive Behavioral Therapy for Fatigue in HL

    • Hans Knoop
  • 18:25–18:45

    Genetic Susceptibility

    • Lindsay Morton

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.